In a changing health care environment, the role of patients in managing their arthritis is increasingly important. Patient education is the primary means for teaching patients how to fulfill this role successfully. The goal of self-management health education is not merely to provide information, but to change subject attitudes and behavior so that patient outcomes are improved. These programs represent a new treatment for arthritis. Arthritis Self-Management Programs are a proven effective intervention, but are limited by the logistics of providing a sufficient number of face-to-face interventions at a sufficient number of sites. This project will evaluate the relative effect on health status and cost- effectiveness of two arthritis patient education programs which utilize different delivery systems. The Arthritis Self-Management Program (ASMP) utilizes a small group, multi-class format. It is taught by trained lay leaders and has been evaluated for effectiveness and has been widely disseminated. The Self-Managed Arthritis Relief Therapy (SMART) Program is a computer-driven, individualized, mail-delivered intervention. Based on pilot study, it is effective in improving health status and reducing health care utilization. In addition, the project will evaluate the generalizability of the SMART program as well as its effectiveness for patients with different diagnoses (OA and RA). It will also determine the attributes of patients who choose and do not choose to participate in patient education programs as well as the attributes of those who complete and do not complete the ASMP and SMART Programs. Through utilization of the ARAMIS data collection system, the project allows us to describe the differences between patients who volunteer to receive patient education and those who refuse patient education. This project is directed at improving patient outcomes in both RA and OA through wide availability of a low-cost, mail-delivered Arthritis Self- Management Program; the next generation in arthritis health education.

Project Start
1998-05-01
Project End
1999-04-30
Budget Start
1997-10-01
Budget End
1998-09-30
Support Year
3
Fiscal Year
1998
Total Cost
Indirect Cost
Name
Stanford University
Department
Type
DUNS #
800771545
City
Stanford
State
CA
Country
United States
Zip Code
94305
Chester Wasko, Mary; Dasgupta, Abhijit; Ilse Sears, Genevieve et al. (2016) Prednisone Use and Risk of Mortality in Patients With Rheumatoid Arthritis: Moderation by Use of Disease-Modifying Antirheumatic Drugs. Arthritis Care Res (Hoboken) 68:706-10
Wasko, Mary Chester M; Dasgupta, Abhijit; Hubert, Helen et al. (2013) Propensity-adjusted association of methotrexate with overall survival in rheumatoid arthritis. Arthritis Rheum 65:334-42
Chakravarty, Eliza F; Hubert, Helen B; Krishnan, Eswar et al. (2012) Lifestyle risk factors predict disability and death in healthy aging adults. Am J Med 125:190-7
Bruce, Bonnie; Fries, James F (2009) Rheumatologist perceptions of sources of health care disparities in minority rheumatoid arthritis patients. J Clin Rheumatol 15:145-7
Chakravarty, Eliza F; Hubert, Helen B; Lingala, Vijaya B et al. (2008) Reduced disability and mortality among aging runners: a 21-year longitudinal study. Arch Intern Med 168:1638-46
Hueber, Wolfgang; Tomooka, Beren H; Zhao, Xiaoyan et al. (2007) Proteomic analysis of secreted proteins in early rheumatoid arthritis: anti-citrulline autoreactivity is associated with up regulation of proinflammatory cytokines. Ann Rheum Dis 66:712-9
Bruce, Bonnie; Fries, James F; Murtagh, Kirsten Naumann (2007) Health status disparities in ethnic minority patients with rheumatoid arthritis: a cross-sectional study. J Rheumatol 34:1475-9
Bruce, Bonnie; Lorig, Kate; Laurent, Diana (2007) Participation in patient self-management programs. Arthritis Rheum 57:851-4
Hueber, Wolfgang; Kidd, Brian A; Tomooka, Beren H et al. (2005) Antigen microarray profiling of autoantibodies in rheumatoid arthritis. Arthritis Rheum 52:2645-55
Bruce, B; Fries, J F (2005) The Arthritis, Rheumatism and Aging Medical Information System (ARAMIS): still young at 30 years. Clin Exp Rheumatol 23:S163-7

Showing the most recent 10 out of 53 publications